Publications by authors named "Kevin McCague"

Claim this Profile
A
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Andrew P Ambrosy, Eugene Braunwald, David A Morrow, Adam D DeVore, Kevin McCague

J Am Coll Cardiol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
Adam D DeVore, Eugene Braunwald, David A Morrow, Carol I Duffy, Andrew P Ambrosy, Kevin McCague

JAMA Cardiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rational and design of the AWAKE-HF study.
Raj M Khandwalla, Kade Birkeland, J Thomas Heywood, Steven Steinhubl, Kevin McCague

ESC Heart Fail· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
Erika M Giblin, Kirkwood F Adams, Larry Hill, Gregg C Fonarow, Fredonia B Williams, Kevin McCague

Am J Cardiol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
Yevgeniy Khariton, Gregg C Fonarow, Suzanne V Arnold, Ann Hellkamp, Michael E Nassif, Kevin McCague

JACC Heart Fail· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
David A Morrow, Eric J Velazquez, Adam D DeVore, Margaret F Prescott, Carol I Duffy, Kevin McCague

Eur Heart J· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
James L Januzzi, Margaret F Prescott, Javed Butler, G Michael Felker, Alan S Maisel, Kevin McCague

JAMA· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Akshay S Desai, Scott D Solomon, Amil M Shah, Brian L Claggett, James C Fang, Kevin McCague

JAMA· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF.
Merrill Thomas, Yevgeniy Khariton, Gregg C Fonarow, Suzanne V Arnold, Larry Hill, Kevin McCague

JACC Heart Fail· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.
Stephen J Greene, Gregg C Fonarow, Adam D DeVore, Puza P Sharma, Muthiah Vaduganathan, Kevin McCague

J Am Coll Cardiol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
David A Morrow, Eric J Velazquez, Adam D DeVore, Akshay S Desai, Carol I Duffy, Kevin McCague

Circulation· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Poghni A Peri-Okonny, Xiaojuan Mi, Yevgeniy Khariton, Krishna K Patel, Laine Thomas, Kevin McCague

JACC Heart Fail· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague

N Engl J Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
Adam D DeVore, C Larry Hill, Laine Thomas, Puza P Sharma, Nancy M Albert, Kevin McCague

Circ Heart Fail· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Stephen J Greene, Javed Butler, Nancy M Albert, Adam D DeVore, Puza P Sharma, Kevin McCague

J Am Coll Cardiol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure.
Yevgeniy Khariton, Michael E Nassif, Laine Thomas, Gregg C Fonarow, Xiaojuan Mi, Kevin McCague

JACC Heart Fail· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
Adam D DeVore, Xiaojuan Mi, Laine Thomas, Puza P Sharma, Nancy M Albert, Kevin McCague

J Am Heart Assoc· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
James L Januzzi, Javed Butler, Emmanuel Fombu, Alan Maisel, Kevin McCague

Am Heart J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry.
Yevgeniy Khariton, Adrian F Hernandez, Gregg C Fonarow, Puza P Sharma, Carol I Duffy, Kevin McCague

Circ Cardiovasc Qual Outcomes· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Eric J Velazquez, David A Morrow, Adam D DeVore, Andrew P Ambrosy, Carol I Duffy, Kevin McCague

Am Heart J· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study.
Michael Charlton, Mary Rinella, Dharmesh Patel, Kevin McCague, Julie Heimbach

Transplantation· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry.
Adam D DeVore, Laine Thomas, Nancy M Albert, Javed Butler, Adrian F Hernandez, Kevin McCague

Am Heart J· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
Samuel F Hunter, Mark Agius, Deborah M Miller, Gary Cutter, Luigi Barbato, Kevin McCague

J Neurol Sci· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Edward Fox, Keith Edwards, Gordon Burch, Daniel R Wynn, Chris LaGanke, Kevin McCague

Mult Scler Relat Disord· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Bruce Hughes, Mark Cascione, Mark S Freedman, Mark Agius, Daniel Kantor, Kevin McCague

Mult Scler Relat Disord· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis